Table 4.
Pathogenic Variant (PV) rate by breast cancer pathology
| Pathology | Total | BRCA1 | BRCA2 | PALB2 | Total PV | % | Total BRCA1/2 | %BRCA1/2 |
|---|---|---|---|---|---|---|---|---|
| G3 BC ERpos her2- | 152 | 1 | 6 | 4 | 11 | 7.24% | 7 | 4.61% |
| G2 BC ERpos her2- | 301 | 0 | 5 | 1 | 6 | 1.99% | 5 | 1.66% |
| G1BC | 156 | 0 | 0 | 0 | 0 | 0.00% | 0 | 0.00% |
| DCIS | 138 | 0 | 2 | 2 | 4 | 2.90% | 2 | 1.45% |
| Lobular | 96 | 0 | 0 | 0 | 0 | 0.00% | 0 | 0.00% |
| HER2+ | 53 | 0 | 1 | 0 | 1 | 1.89% | 1 | 1.89% |
| TNT | 113 | 7 | 2 | 1 | 10 | 8.85% | 9 | 7.96% |
| IDC grade NOS | 52 | 1 | 2 | 1 | 4 | 7.69% | 3 | 5.77% |
| Total | 1061 | 9 | 18 | 9 | 36 | 3.39% | 27 | 2.54% |
BC, breast cancer; G1BC, grade 1 invasive ductal carcinoma; G2BC, grade 2 invasive ductal carcinoma; G3BC, grade 3 invasive ductal carcinoma; DCIS -disseminated carcinoma in situ; IDC, invasive ductal carcinoma; NOS, not otherwise stated; TNT, triple negative tumor; PV, pathogenic variant.